Metastatic Pancreatic Ductal Adenocarcinoma

Oncology
8
Pipeline Programs
8
Companies
7
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
5
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 4 programs with unclassified modality

On Market (1)

Approved therapies currently available

GSK
OJJAARAApproved
momelotinib
GSK
oral2023

Competitive Landscape

7 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
1 program
1
1
MomelotinibPhase 3Small Molecule1 trial
Active Trials
NCT02101021Terminated25Est. Apr 2017
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
ChiauranibPhase 3Small Molecule1 trial
Active Trials
NCT07445295Not Yet RecruitingEst. Nov 2028
Arcus Biosciences
1 program
1
QuemliclustatPhase 3Small Molecule1 trial
Active Trials
NCT06608927Active Not RecruitingEst. Nov 2030
Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
1 program
1
Relacorilant, 100 mg and 25 mgPhase 31 trial
Active Trials
NCT04329949Terminated43Est. Mar 2022
CT
1 program
1
TQB2868 InjectionPhase 31 trial
Active Trials
NCT07165951RecruitingEst. Dec 2028
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-04136309Phase 21 trial
Active Trials
NCT02732938Terminated22Est. Oct 2017
Alligator Bioscience
1 program
1
CD40 agonist mitazalimab in combination with chemotherapyPhase 1/21 trial
Active Trials
NCT04888312Active Not RecruitingEst. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Chipscreen BiosciencesChiauranib
Chia Tai TianQing Pharmaceutical GroupTQB2868 Injection
Arcus BiosciencesQuemliclustat
Corcept TherapeuticsRelacorilant, 100 mg and 25 mg
GSKMomelotinib
PfizerPF-04136309
Alligator BioscienceCD40 agonist mitazalimab in combination with chemotherapy

Clinical Trials (7)

Total enrollment: 90 patients across 7 trials

NCT07445295Chipscreen BiosciencesChiauranib

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Start: Mar 2026Est. completion: Nov 2028
Phase 3Not Yet Recruiting
NCT07165951Chia Tai TianQing Pharmaceutical GroupTQB2868 Injection

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Start: Dec 2025Est. completion: Dec 2028
Phase 3Recruiting
NCT06608927Arcus BiosciencesQuemliclustat

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Start: Dec 2024Est. completion: Nov 2030
Phase 3Active Not Recruiting
NCT04329949Corcept TherapeuticsRelacorilant, 100 mg and 25 mg

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Start: Jun 2020Est. completion: Mar 202243 patients
Phase 3Terminated
NCT02101021GSKMomelotinib

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Start: Jun 2014Est. completion: Apr 201725 patients
Phase 3Terminated
NCT02732938PfizerPF-04136309

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

Start: May 2016Est. completion: Oct 201722 patients
Phase 2Terminated
NCT04888312Alligator BioscienceCD40 agonist mitazalimab in combination with chemotherapy

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

Start: Sep 2021Est. completion: Jun 2026
Phase 1/2Active Not Recruiting

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
6h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
Florham Park, NJ
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
South San Francisco, CA
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
North Chicago, IL
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 90 patients
8 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)